Yohei Hisada1, Nigel Mackman. 1. Division of Hematology and Oncology, Department of Medicine, UNC Blood Research Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Abstract
PURPOSE OF REVIEW: Tissue factor (TF) is released from cancer cells and tumors in the form of extracellular vesicles (EVs). This review summarizes our current knowledge of the mechanisms of release of TF-positive EVs (TF+EVs) from cancer cells and the effect of these TF+EVs on cultured endothelial cells. In addition, we will summarize the contribution of TF+EVs to thrombosis in mice, and the association between plasma EVTF activity and venous thrombosis as well as survival of cancer patients. RECENT FINDINGS: The release of TF+EVs from cancer cells is regulated by multiple factors, including hypoxia, epithelial-mesenchymal transition, and various intracellular signaling pathways. Cancer cell-derived, TF+EVs confer procoagulant activity to endothelial cells and induce the expression of adhesion proteins and IL-8. In addition, they contribute to thrombosis by directly activating the coagulation system and by generating thrombin that activates platelets in mouse models. Finally, there is an association between EVTF activity and venous thrombosis in pancreatic cancer patients as well as mortality in cancer patients. SUMMARY: Cancer cell-derived TF+EVs bind to and activate endothelial cells. In addition, they serve as biomarkers of survival of cancer patients and venous thrombosis in pancreatic cancer patients.
PURPOSE OF REVIEW: Tissue factor (TF) is released from cancer cells and tumors in the form of extracellular vesicles (EVs). This review summarizes our current knowledge of the mechanisms of release of TF-positive EVs (TF+EVs) from cancer cells and the effect of these TF+EVs on cultured endothelial cells. In addition, we will summarize the contribution of TF+EVs to thrombosis in mice, and the association between plasma EVTF activity and venous thrombosis as well as survival of cancerpatients. RECENT FINDINGS: The release of TF+EVs from cancer cells is regulated by multiple factors, including hypoxia, epithelial-mesenchymal transition, and various intracellular signaling pathways. Cancer cell-derived, TF+EVs confer procoagulant activity to endothelial cells and induce the expression of adhesion proteins and IL-8. In addition, they contribute to thrombosis by directly activating the coagulation system and by generating thrombin that activates platelets in mouse models. Finally, there is an association between EVTF activity and venous thrombosis in pancreatic cancerpatients as well as mortality in cancerpatients. SUMMARY:Cancer cell-derived TF+EVs bind to and activate endothelial cells. In addition, they serve as biomarkers of survival of cancerpatients and venous thrombosis in pancreatic cancerpatients.
Authors: J W Blom; J P M Vanderschoot; M J Oostindiër; S Osanto; F J M van der Meer; F R Rosendaal Journal: J Thromb Haemost Date: 2006-03 Impact factor: 5.824
Authors: Ronnie Tung-Ping Poon; Cecilia Pik-Yuk Lau; Joanna Wen-Ying Ho; Wan-Ching Yu; Sheung-Tat Fan; John Wong Journal: Clin Cancer Res Date: 2003-11-01 Impact factor: 12.531
Authors: Olga Melnichnikova; Yulia Zhilenkova; Olga Sirotkina; Ekaterina Zolotova; Konstantin Pishchulov; Malik Tastanbekov; Artem Paltsev; Maria Simakova Journal: Front Cardiovasc Med Date: 2022-06-23
Authors: Sameera Peraramelli; Qi Zhou; Qin Zhou; Bettina Wanko; Lei Zhao; Toshihiko Nishimura; Thomas H Leung; Seiya Mizuno; Mamoru Ito; Timothy Myles; Thomas M Stulnig; John Morser; Lawrence L K Leung Journal: J Thromb Haemost Date: 2022-02-16 Impact factor: 16.036
Authors: Marcela Rosas; David A Slatter; Samya G Obaji; Jason P Webber; Jorge Alvarez-Jarreta; Christopher P Thomas; Maceler Aldrovandi; Victoria J Tyrrell; Peter V Jenkins; Valerie B O'Donnell; Peter W Collins Journal: PLoS One Date: 2020-10-08 Impact factor: 3.240
Authors: Young Jun Shim; Victor Chatterjee; Shadi Swaidani; Ravi Kumar Alluri; Suman Kundu; Alona Merkulova; Dana Angelini; Dewen You; Samantha A Whitney; Edward P Feener; John Barnard; Alvin H Schmaier; Alok A Khorana; Keith R McCrae Journal: Blood Adv Date: 2021-11-23